Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib
NCT01459757 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 322
Last updated 2013-06-19
Summary
Retrospective correlation of clinical outcomes data with mutational status in GIST subjects treated with sunitinib.
Conditions
Interventions
- OTHER
-
non-interventional
Non-interventional; Mutational status data analyzed previously but not collected in the A6181036 study, will be correlated wth A6181036 clinical outcomes data collected during the A6181036 study.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-10-31
- Primary Completion
- 2013-04-30
- Completion
- 2013-04-30
Countries
- United States
- Australia
- Belgium
- Canada
- Denmark
- Finland
- France
- Germany
- India
- Netherlands
- Poland
- Slovakia
- South Korea
- Spain
- Switzerland
- United Kingdom
Study Locations
More Related Trials
-
Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor
NCT00793871 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
NCT05734105 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
NCT03673501 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer
NCT00411151 ·Status: COMPLETED ·Phase: PHASE2
-
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
NCT05366816 ·Status: RECRUITING ·Phase: PHASE2
-
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
NCT01068769 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
NCT02691793 ·Status: COMPLETED ·Phase: PHASE4
-
Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs
NCT02889328 ·Status: COMPLETED ·Phase: PHASE2
-
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST
NCT05751733 ·Status: RECRUITING ·Phase: NA
-
Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer
NCT00555672 ·Status: COMPLETED ·Phase: PHASE1
-
Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients
NCT07096609 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Sorafenib for Imatinib/Sunitinib-failed GIST
NCT01091207 ·Status: COMPLETED ·Phase: PHASE2
-
Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients
NCT01934452 ·Status: COMPLETED
-
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy
NCT01646593 ·Status: NO_LONGER_AVAILABLE
-
A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
NCT00094029 ·Status: APPROVED_FOR_MARKETING
-
Evaluation of Patients With Bulky GIST Using Sunitinib
NCT01054911 ·Status: TERMINATED ·Phase: NA
-
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme
NCT00535379 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)
NCT01039519 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer
NCT00748358 ·Status: COMPLETED ·Phase: PHASE2
-
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
NCT01689376 ·Status: NO_LONGER_AVAILABLE
-
Sunitinib to Treat Recurrent Brain Cancer
NCT00923117 ·Status: TERMINATED ·Phase: PHASE2
-
Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
NCT00684645 ·Status: COMPLETED
-
Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).
NCT00716820 ·Status: COMPLETED
-
Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
NCT00113529 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
NCT07218926 ·Status: RECRUITING ·Phase: PHASE3